Vla15 221 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Vla15 221. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Vla15 221 Today - Breaking & Trending Today
21st Austria weekly - Valneva 07/09/2023 [pic1]Valneva: Specialty vaccine company and Pfizer announced positive pediatric adolescent immunogenicity safety data for their Lyme disease candidate VLA15 when given as a booster. These results from the VLA15-221 Phase 2 study showed strong anamnestic antibody response all serotypes in 5 to 11 years of age participants 12 17 age well adults 18 65 one month after administration booster dose month 19. “Protection against is important anyone who lives or spends time outdoors areas where endemic. This vital improve our understanding how vaccination may help protect both children this potentially devastating disease ” said Annaliesa Anderson Senior Vice President ....
14.03.2021 Valneva: Valneva, a specialty vaccine company focused on prevention of diseases with major unmet needs, and Pfizer today announced initiation of study VLA15-221. The VLA15-221 study builds on previous positive Phase 2 studies, incorporates new dose regimens and is anticipated to be the final Phase 2 study readout before a decision to progress into pivotal Phase 3 studies. As announced in December 2020, VLA15-221 is a randomized, observer-blind, placebo-controlled Phase 2 study. It will be the first VLA15 study to include a pediatric population (aged 5-17 years). Overall, the study will enroll approximately 600 healthy participants (aged 5-65 years) who will receive VLA15 or placebo. It will compare the three-dose vaccination schedule (Month 0-2-6) with a two-dose schedule (Month 0-6). Juan Carlos Jaramillo, Chief Medical Officer of Valneva commented, “This trial initiation marks an important step in the development of VLA15 toward a potential licensure. Includin ....